|
| 1 |
Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
Haruka Otake, Satohiro Matsumoto, Hirosato Mashima
Intest Res.2022;20(4):464-474. Published online 2022 March 31
DOI: http://dx.doi.org/10.5217/ir.2021.00139
|
|
| 2 |
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
Brigida Barberio, Edoardo Vincenzo Savarino, Timothy Card, Cristina Canova, Francesco Baldisser, Alessandro Gubbiotti, Davide Massimi, Matteo Ghisa, Fabiana Zingone
Intest Res.2022;20(1):114-123. Published online 2021 August 4
DOI: http://dx.doi.org/10.5217/ir.2021.00037
|
|
| 3 |
Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea
Myeung-su Lee, Chang Hoon Lee, Hye Soon Lee, Yoon-Kyoung Sung, Jung Ran Choi, Kyungsu Park, Mi-Kyoung Lim, Byoong Yong Choi, Hyoun-Ah Kim, Seung Won Choi, Yusun Lee, Wan-Hee Yoo
|
|
| 4 |
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, Takashi Hagiwara, Takeshi Kawaberi, Haruhiko Ogata, Toshiyuki Matsui, Mamoru Watanabe, Toshifumi Hibi
Intest Res.2021;19(4):408-418. Published online 2020 November 20
DOI: http://dx.doi.org/10.5217/ir.2020.00025
|
|
| 5 |
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
Intest Res.2021;19(4):419-429. Published online 2020 November 10
DOI: http://dx.doi.org/10.5217/ir.2020.00033
|
|
| 6 |
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
Yasuo Suzuki, Takashi Hagiwara, Mariko Kobayashi, Kazuo Morita, Tomoyo Shimamoto, Toshifumi Hibi
Intest Res.2021;19(3):301-312. Published online 2020 August 21
DOI: http://dx.doi.org/10.5217/ir.2020.00013
|
|
| 7 |
Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
So Yoon Choi, Young Ok Choi, Yon Ho Choe, Ben Kang
|
|
| 8 |
Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies
Hanna van Rheenen, Patrick Ferry van Rheenen
|
|
| 9 |
Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park
Yonsei Med J.2020;61(1):48-55. Published online 2019 December 23
DOI: http://dx.doi.org/10.3349/ymj.2020.61.1.48
|
|
| 10 |
The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis
Suhwan Lee, Yu Jeong Park, Joo Yong Lee
|
|
| 11 |
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chian Lim, Wai Keung Leung, Raja Affendi Raja Ali, Deng Chyang Wu, Evan Ong, Nazri Mustaffa, Julajak Limsrivilai, Tadakazu Hisamatsu, Suk Kyun Yang, Qin Ouyang, Richard Geary, Janaka H De Silva, Rungsun Rerknimitr, Marcellus Simadibrata, Murdani Abdullah, Rupert WL Leong
Intest Res.2019;17(3):285-310. Published online 2019 May 31
DOI: http://dx.doi.org/10.5217/ir.2019.00026
|
|
| 12 |
Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
Rintaro Moroi, Katsuya Endo, Katsutoshi Yamamoto, Takeo Naito, Motoyuki Onodera, Masatake Kuroha, Yoshitake Kanazawa, Tomoya Kimura, Yoichi Kakuta, Atsushi Masamune, Yoshitaka Kinouchi, Tooru Shimosegawa
Intest Res.2019;17(1):94-106. Published online 2018 December 3
DOI: http://dx.doi.org/10.5217/ir.2018.00048
|
|
| 13 |
Successful Treatment of Refractory Cutaneous Polyarteritis Nodosa with Adalimumab
Eunyoung Ahn, Min Wook So
J Rheum Dis.2018;25(4):302-305. Published online 2018 October 1
DOI: http://dx.doi.org/10.4078/jrd.2018.25.4.302
|
|
| 14 |
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
Vandana Midha, Ramit Mahajan, Varun Mehta, Vikram Narang, Arshdeep Singh, Kirandeep Kaur, Ajit Sood
Intest Res.2018;16(1):83-89. Published online 2018 January 18
DOI: http://dx.doi.org/10.5217/ir.2018.16.1.83
|
|
| 15 |
A Case of Refractory Oral Aphthous Ulcer Successfully Treated with Adalimumab
Jinyeong Kim, Myung-jin Song, Hye-Jin Jeong, Soo-Kyung Cho, Yoon-Kyoung Sung
J Rheum Dis.2017;24(3):157-160. Published online 2017 October 31
DOI: http://dx.doi.org/10.4078/jrd.2017.24.3.157
|
|
| 16 |
Comparative Efficacy and Safety of Secukinumab and Adalimumab in Patients with Active Ankylosing Spondylitis: A Bayesian Network Meta-analysis of Randomized Controlled Trials
Young Ho Lee, Gwan Gyu Song
J Rheum Dis.2017;24(4):211-219. Published online 2017 October 31
DOI: http://dx.doi.org/10.4078/jrd.2017.24.4.211
|
|
| 17 |
Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
Wei-Chen Lin, Jen-Wei Chou, Hsu-Heng Yen, Wen-Hung Hsu, Hung-Hsin Lin, Jen-Kou Lin, Chiao-Hsiung Chuang, Tien-Yu Huang, Horng-Yuan Wang, Shu-Chen Wei, Jau-Min Wong
Intest Res.2017;15(4):487-494. Published online 2017 October 23
DOI: http://dx.doi.org/10.5217/ir.2017.15.4.487
|
|
| 18 |
Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
Cheng-Chun Ji, Shota Takano
Intest Res.2017;15(2):182-186. Published online 2017 April 27
DOI: http://dx.doi.org/10.5217/ir.2017.15.2.182
|
|
| 19 |
Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
Won Jae Song, Ben Kang, So Yoon Choi, Yon Ho Choe
|
|
| 20 |
Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
Jang Wook Lee, Chang Hwan Choi, Ji Hoon Park, Jeong Wook Kim, Sang Bum Kang, Ja Seol Koo, Young-Ho Kim, You Sun Kim, Young Eun Joo, Sae Kyung Chang
Intest Res.2016;14(2):146-151. Published online 2016 April 27
DOI: http://dx.doi.org/10.5217/ir.2016.14.2.146
|
|
